LeMaitre Vascular is expected to report Q3 2026 revenue of $67.39 million and adjusted EPS of $0.69, with the current stock price of $80.94 trading at a significant discount to the $107.00 analyst consensus target.
Investors are primarily focused on the company’s ability to maintain high gross margins and the continued international rollout of its Artegraft product line. While the previous quarter saw a slight revenue miss, management’s expansion into European and APAC markets is expected to drive 10.4% year-over-year top-line growth. Sustained pricing power in niche vascular categories remains the central pillar of the bull case heading into the year-end results.